8 sources
Moderna released full data on its closely watched cancer vaccine developed with Merck.
Original
Financial Times29h ago
Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty…
OriginalModerna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release.
Original
CNN32h ago
When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were exhilarated. And that was before its makers had even disclosed just how well the therapy worked.
OriginalModerna released full data on its closely watched cancer vaccine developed with Merck.
OriginalMelanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty…
OriginalFinancial Times32h ago
Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty…
Original
The New York Times32h ago
Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty…
Original
